Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668534
Funder
Australian Research Council
Funding Amount
$770,000.00
Summary
High resolution bioanalytical Fourier transform mass spectrometer combined with liquid chromatograph. This project extends a network of advanced technology for bioanalysis that enables discoveries in biotechnology, molecular medicine and biochemistry. The proposed equipment includes the most powerful mass spectrometer (MS) currently available for bioanalysis to complement an existing network of instruments at four universities in Sydney. These include 3 of 4 nodes of the Australian Proteome Anal ....High resolution bioanalytical Fourier transform mass spectrometer combined with liquid chromatograph. This project extends a network of advanced technology for bioanalysis that enables discoveries in biotechnology, molecular medicine and biochemistry. The proposed equipment includes the most powerful mass spectrometer (MS) currently available for bioanalysis to complement an existing network of instruments at four universities in Sydney. These include 3 of 4 nodes of the Australian Proteome Analysis Facility (APAF). The new technology is a missing link in bioanalytical capability where other instruments are not sufficiently sensitive. The instrument will be managed by MS specialists at the Bioanalytical Mass Spectrometry Facility at UNSW (www.bmsf.unsw.edu.au) where access by and training of users is well established.Read moreRead less
Characterization of erythroid differentiation related factor (EDRF): a novel a-globin binding protein. Hemoglobin, a four-subunit protein comprising two alpha and two beta polypeptide chains, is the essential oxygen transporter found in all mammals. Problems with the synthesis of hemoglobin can give rise to a range of common and serious human disorders, including thalassaemia and anemia. We have discovered a protein, EDRF, that appears to interact directly with alpha-globin (but not beta-globin) ....Characterization of erythroid differentiation related factor (EDRF): a novel a-globin binding protein. Hemoglobin, a four-subunit protein comprising two alpha and two beta polypeptide chains, is the essential oxygen transporter found in all mammals. Problems with the synthesis of hemoglobin can give rise to a range of common and serious human disorders, including thalassaemia and anemia. We have discovered a protein, EDRF, that appears to interact directly with alpha-globin (but not beta-globin) and to play a role in the regulation of hemoglobin production. We now seek to understand the nature of this interaction at a molecular level and mechanistic level.Read moreRead less
A novel approach to fighting fungal infections: targeted disruption of hydrophobin monolayers. Fungal infestations of important crops such as cotton cause large economic losses to Australian agriculture while in the medical sector, fungal infections are responsible for high levels of mortality in immunocompromised patients. Our research will provide a new approach to fighting fungal infections by targeting the hydrophobin proteins, which form a robust coating on fungal aerial structures, such as ....A novel approach to fighting fungal infections: targeted disruption of hydrophobin monolayers. Fungal infestations of important crops such as cotton cause large economic losses to Australian agriculture while in the medical sector, fungal infections are responsible for high levels of mortality in immunocompromised patients. Our research will provide a new approach to fighting fungal infections by targeting the hydrophobin proteins, which form a robust coating on fungal aerial structures, such as spores. This layer is critical for fungal growth and reproduction and confers water resistance and tolerance to harsh conditions. Our work seeks to develop reagents that can specifically block regions on the protein that are responsible for forming this coating.
Read moreRead less
Zinc finger domains as scaffolds for protein engineering. While great advances have been made in pharmaceutical design and discovery, it is clear that new types of drugs are needed for the better management of a wide range of diseases (e.g. cancers, autoimmune diseases, viral infections). Many of these diseases arise from inappropriate interactions between intracellular biological macromolecules. My aim is to develop a range of novel therapeutic proteins based on naturally existing zinc-binding ....Zinc finger domains as scaffolds for protein engineering. While great advances have been made in pharmaceutical design and discovery, it is clear that new types of drugs are needed for the better management of a wide range of diseases (e.g. cancers, autoimmune diseases, viral infections). Many of these diseases arise from inappropriate interactions between intracellular biological macromolecules. My aim is to develop a range of novel therapeutic proteins based on naturally existing zinc-binding protein domains with the goal of selectively blocking these inappropriate interactions. Additionally, these engineered proteins have potential uses as biochemical tools such as to help delineate the functions of natural proteins with no known functions.Read moreRead less
Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis. The purpose of this study is to identify novel biomarkers in the tears of patients with CaP. The use of the several techniques will increase the chance of success and enable us to find more diagnostic markers. If successful, the identified proteins may be used to diagnose and determine the stage of cancer. This will help guide clinicians in choosing the best treatment methods for an individual patient. The m ....Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis. The purpose of this study is to identify novel biomarkers in the tears of patients with CaP. The use of the several techniques will increase the chance of success and enable us to find more diagnostic markers. If successful, the identified proteins may be used to diagnose and determine the stage of cancer. This will help guide clinicians in choosing the best treatment methods for an individual patient. The markers may also be used to monitor the disease progress and the effects of treatment. The results from this study may improve the prognosis of CaP patients.Read moreRead less
Identification of novel biomarkers for diabetic retinopathy in tears. There are around 134,000 people with diabetic retinopathy in Australia. The disease affects patients' physical and mental state and economical and social cost is enormous. This research aims to find new biomarkers for the disease which may lead to better treatment and management. Patient's quality of life may be significantly improved by early diagnosis and treatment and the burden to the community reduced. This project also g ....Identification of novel biomarkers for diabetic retinopathy in tears. There are around 134,000 people with diabetic retinopathy in Australia. The disease affects patients' physical and mental state and economical and social cost is enormous. This research aims to find new biomarkers for the disease which may lead to better treatment and management. Patient's quality of life may be significantly improved by early diagnosis and treatment and the burden to the community reduced. This project also gives industrial partners the opportunity to develop new products to diagnose and monitor the disease.Read moreRead less
The basis of recognition and disposal of dysfunctional proteins by clusterin. When proteins become damaged they can precipitate. A blood protein called clusterin prevents precipitation of damaged proteins. Clusterin does this by forming complexes with the damaged proteins. Clusterin is the first blood protein known to do this. We will discover which parts of clusterin are responsible for this activity. We will also discover whether cells can take up and dispose of the complexes of clusterin and ....The basis of recognition and disposal of dysfunctional proteins by clusterin. When proteins become damaged they can precipitate. A blood protein called clusterin prevents precipitation of damaged proteins. Clusterin does this by forming complexes with the damaged proteins. Clusterin is the first blood protein known to do this. We will discover which parts of clusterin are responsible for this activity. We will also discover whether cells can take up and dispose of the complexes of clusterin and damaged proteins. This work is important because some diseases (eg, Alzheimers disease) involve the toxic effects of abnormal protein precipitation. Understanding how clusterin works may help in developing better treatments for these diseases.Read moreRead less
Defining in molecular terms cis-inhibition as a means to inhibit Notch signaling. Normal development of a baby and our health after birth is dependent on how our cells behave. Signals move between cells and within them to tell them what to do. Proteins interacting with other proteins mostly transmit these signals. This research focuses on a protein named Notch and the signals that it transmits. Notch functions in normal processes, such as blood vessel formation; but abnormal signaling causes and ....Defining in molecular terms cis-inhibition as a means to inhibit Notch signaling. Normal development of a baby and our health after birth is dependent on how our cells behave. Signals move between cells and within them to tell them what to do. Proteins interacting with other proteins mostly transmit these signals. This research focuses on a protein named Notch and the signals that it transmits. Notch functions in normal processes, such as blood vessel formation; but abnormal signaling causes and/or contributes to pathological situations such as degenerative disease and cancer. We are working to understand how the Notch signal is made and how to control it when it is abnormal. This will allow new medications to be developed to help people who have cancer and other Notch-related illnessesRead moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100142
Funder
Australian Research Council
Funding Amount
$500,000.00
Summary
An integrated liquid chromatography mass spectrometry nuclear magnetic resonance (LC-MS-NMR) facility for applications in proteomics and organic chemistry. This application completes the requested liquid chromatography mass spectrometry nuclear magnetic resonance (LCMS-NMR) facility and will allow the training of over 150 researchers, significantly enhancing their research productivity and translation of outcomes in areas of national importance. New breakthroughs in drug development, smart mate ....An integrated liquid chromatography mass spectrometry nuclear magnetic resonance (LC-MS-NMR) facility for applications in proteomics and organic chemistry. This application completes the requested liquid chromatography mass spectrometry nuclear magnetic resonance (LCMS-NMR) facility and will allow the training of over 150 researchers, significantly enhancing their research productivity and translation of outcomes in areas of national importance. New breakthroughs in drug development, smart materials, organic electronic materials and biomedical research require routine access to cutting edge technology. The LCMS-NMR augments the capabilities of our research teams at the forefront of these efforts. These include understanding the impact of the environment on plant and animal development, pest animal control, development of new biotechnology tools, new drugs and new methods for the detection of narcotics and explosives.Read moreRead less